• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Trulieve Cannabis (TRLV) Opens Marco Island Store As Its Fair Value Narrative Stays In Focus

    Simply Wall St·07/23/2026 20:14:35
    Listen to the news

    Trulieve Cannabis (TRLV) is in focus after announcing a new medical cannabis dispensary on Marco Island, Florida, with a July 24 grand opening that includes promotions and a broad mix of in house and partner brands.

    See our latest analysis for Trulieve Cannabis.

    The new Marco Island opening comes as Trulieve Cannabis trades at US$8.67, with a 90 day share price return of 13.88% and a 1 year total shareholder return of 95.27%, while the 5 year total shareholder return remains down 73.21%. This suggests that recent momentum has picked up against a much weaker long term record.

    If Trulieve’s latest opening has you thinking about where growth might come from next in healthcare and biotech, it could be worth checking out 41 healthcare AI stocks.

    After a sharp rebound in Trulieve Cannabis, the share price still sits well below both analyst targets and some intrinsic value estimates. So how far does that gap run once you line the current US$8.67 price up against them?

    Most Popular Narrative: 55.3% Undervalued

    At a last close of $8.67 versus a widely followed fair value estimate of about $19.42, the Trulieve Cannabis narrative points to a large valuation gap that hinges on how its medical platform scales and how cash is redeployed.

    A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.

    Read the complete narrative.

    Want to see what has to change for Trulieve Cannabis to justify that higher fair value? The narrative leans heavily on a sharp earnings swing and much higher long term profit margins. Curious how those assumptions stack up against a shrinking revenue base and a different future valuation multiple? The full narrative joins those pieces together and shows how they support the current fair value.

    Result: Fair Value of $19.42 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Trulieve Cannabis still faces uncertainty around federal rescheduling outcomes and tax relief, while ongoing pricing pressure could limit the earnings rebound that underpins the current narrative.

    Find out about the key risks to this Trulieve Cannabis narrative.

    Next Steps

    Want a balanced take on Trulieve Cannabis after assessing both its risks and potential rewards? Move quickly, review the underlying numbers, and then check 4 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Trulieve Cannabis?

    Do not stop at Trulieve Cannabis. Broaden your watchlist with other clear, data backed ideas so you are not relying on a single stock story.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.